Highnoon Laboratories Limited (PSX: HINOON) has announced that it is exploring a potential acquisition of a target company as part of its strategic growth plan.
Read More: Dewan Cement Appoints Ishtiaq Ahmad as Chairman, Ghazanfar Baber Siddiqi as CEO
The move is aimed at strengthening the company’s market position, broadening its product portfolio, and creating operational and commercial synergies. According to the company’s filing with the Pakistan Stock Exchange, the acquisition is expected to support business expansion, improve market access, and enhance distribution efficiencies.
The acquisition is currently in the evaluation stage. Highnoon Laboratories stated that it will proceed with the transaction only after completing comprehensive due diligence, negotiating and executing definitive agreements, and receiving all necessary corporate and regulatory approvals.
The company has committed to keeping its shareholders and stakeholders informed as the process advances. If successful, this strategic acquisition could significantly bolster Highnoon’s competitive position in the pharmaceutical sector, opening up opportunities for portfolio diversification and revenue growth in both domestic and regional markets.
